Steven Greenberg, MD
Neurology · Boston, MANPI 1508847310
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $44,879 of the $46,246 with a category attached, or 97.0%. Alnylam Pharmaceuticals Inc. accounts for 67.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $32,191 and has fallen 82.9% since, to $5,500 in 2025. Among neurology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 18 payments — averaging $2569.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$31K
- Bayer$7K
- E.r. Squibb & Sons, L.L.C.$7K
- Lilly USA, LLC$1K
- Eli Lilly$625
What the payments were for
- Consulting fees$44,87997%
- Food & beverage$1870%
- Education$1,1803%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 7 | $31,191 |
| Bayer | 6 | $6,750 |
| E.r. Squibb & Sons, L.L.C. | 3 | $6,500 |
| Lilly USA, LLC | 1 | $1,180 |
| Eli Lilly | 1 | $625 |
How this compares
$46,246 in reported general payments places this provider in the 90th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $13,107 |
| Memantine Hcl | 25 | $1,936 |
| Minocycline Hcl | 15 | $457 |
| Levetiracetam | 13 | $438 |
Paid to pharmacies, not to this prescriber.
Other neurology in Boston
- Christopher WrightBoston$2.5M
- Thomas ScammellBoston$617K
- Alfred SandrockBoston$490K
- Pushpa NarayanaswamiBoston$420K
- Roy FreemanBoston$390K
- Michael LevyBoston$387K
- Leeann BurtonBoston$325K
- Ilena GeorgeBoston$316K
- Andrew BudsonBoston$304K
- Denis BalabanBoston$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.